Trial Profile
A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 04 Feb 2021 Status changed from recruiting to discontinued as study terminated by sponsor owing to slow enrollment.
- 31 Dec 2018 Planned End Date changed from 30 Mar 2019 to 30 Oct 2019.
- 31 Dec 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jun 2019.